• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Isis Pharmaceuticals

Isis Pharmaceuticals

Isis Pharmaceuticals ISIS

Last Price$52.75Day Change (%)2.41%
Open Price$51.65Day Change ($)1.24
Day Range51.31–52.7752-Week Range22.25–62.66

As of Wed 11/26/2014 04:51 PM EST | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Isis Pharmaceuticals Initiates Phase 3 Study of ISIS -SMN Rx in Children With Spinal Muscular Atrophy

    Isis Pharmaceuticals Initiates Phase 3 Study of ISIS -SMN Rx in Children With Spinal Muscular Atrophy

  2. Cure SMA Presents Isis Pharmaceuticals with SMA Breakthrough Award

    Cure SMA Presents Isis Pharmaceuticals with SMA Breakthrough Award

  3. AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods

    AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods

  4. Isis Pharmaceuticals to Present at Upcoming Investor Conferences

    Isis Pharmaceuticals to Present at Upcoming Investor Conferences

  5. ISIS -STAT3 Rx and ISIS -AR Rx Data Presented by AstraZeneca at European Cancer Symposium

    ISIS -STAT3 Rx and ISIS -AR Rx Data Presented by AstraZeneca at European Cancer Symposium

  6. Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association

    Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association

  7. Strong bull trend reaches latest technical test

    Strong bull trend reaches latest technical test

  8. Ask.com Reveals the Top Searches of 2014; Makes Predictions for the Year Ahead

    Ask.com Reveals the Top Searches of 2014; Makes Predictions for the Year Ahead

  9. Who remembers when ISIS and Ebola caused panic in the markets?

    Who remembers when ISIS and Ebola caused panic in the markets?

  10. 'Downton Abbey' dog Isis will not be killed off: Hugh Bonneville

    'Downton Abbey' dog Isis will not be killed off: Hugh Bonneville

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.